Literature DB >> 19692116

Gout.

Pascal Richette1, Thomas Bardin.   

Abstract

Gout is a common arthritis caused by deposition of monosodium urate crystals within joints after chronic hyperuricaemia. It affects 1-2% of adults in developed countries, where it is the most common inflammatory arthritis in men. Epidemiological data are consistent with a rise in prevalence of gout. Diet and genetic polymorphisms of renal transporters of urate seem to be the main causal factors of primary gout. Gout and hyperuricaemia are associated with hypertension, diabetes mellitus, metabolic syndrome, and renal and cardiovascular diseases. Non-steroidal anti-inflammatory drugs and colchicine remain the most widely recommended drugs to treat acute attacks. Oral corticosteroids could be an alternative to these drugs. Interleukin 1beta is a pivotal mediator of acute gout and could become a therapeutic target. When serum uric acid concentrations are lowered below monosodium urate saturation point, the crystals dissolve and gout can be cured. Patient education, appropriate lifestyle advice, and treatment of comorbidities are an important part of management of patients with gout. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19692116     DOI: 10.1016/S0140-6736(09)60883-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  249 in total

1.  Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors:  Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal:  Drug Dev Res       Date:  2011-12-29       Impact factor: 4.360

2.  Effects of SLC2A9 variants on uric acid levels in a Korean population.

Authors:  Jae Woong Sull; Eun Jung Park; Myoungsook Lee; Sun Ha Jee
Journal:  Rheumatol Int       Date:  2012-01-03       Impact factor: 2.631

3.  Pegloticase.

Authors:  Naomi Schlesinger; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

4.  Oral colchicine (colcrys®) in the treatment and prophylaxis of gout†: profile report.

Authors:  Lily P H Yang
Journal:  Drugs Aging       Date:  2010-10-01       Impact factor: 3.923

Review 5.  Inflammasome-mediated autoinflammatory disorders.

Authors:  Shruti P Wilson; Suzanne L Cassel
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

6.  Gout in pediatric renal transplant recipients.

Authors:  Johannes Trück; Guido F Laube; Rodo O von Vigier; Philippe Goetschel
Journal:  Pediatr Nephrol       Date:  2010-07-18       Impact factor: 3.714

Review 7.  T2 black lesions on routine knee MRI: differential considerations.

Authors:  Vibhor Wadhwa; Gina Cho; Daniel Moore; Parham Pezeshk; Katherine Coyner; Avneesh Chhabra
Journal:  Eur Radiol       Date:  2015-09-29       Impact factor: 5.315

Review 8.  Hyperuricemia and cardiovascular risk.

Authors:  Davide Grassi; Giovambattista Desideri; Anna Vittoria Di Giacomantonio; Paolo Di Giosia; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-02-20

9.  Association of DNA methyltransferase polymorphisms with susceptibility to primary gouty arthritis.

Authors:  Xiaowu Zhong; Yuanhong Peng; Chengjiao Yao; Yufeng Qing; Qibin Yang; Xiaolan Guo; Wenguang Xie; Mingcai Zhao; Xiaoming Cai; Jing-Guo Zhou
Journal:  Biomed Rep       Date:  2016-08-26

10.  Angiogenic and innate immune responses triggered by PRP in tendon cells are not modified by hyperuricemia.

Authors:  Isabel Andia; Eva Rubio-Azpeitia
Journal:  Muscles Ligaments Tendons J       Date:  2014-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.